Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2015 - 2017)

Aytu Biopharma (AYTU) has 3 years of Non-Current Deffered Revenue data on file, last reported at $1451.0 in Q2 2017.

• On a quarterly basis, Non-Current Deffered Revenue fell 82.34% year-over-year to $1451.0 in Q2 2017; TTM through Jun 2017 was $1451.0, a 82.34% decrease from a year earlier, with the FY2017 full-year figure at $1451.0, down 82.34% from the prior year.
• Non-Current Deffered Revenue for Q2 2017 stood at $1451.0, down from $3119.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for AYTU reached as high as $383036.0 in Q4 2015 and fell as low as $1449.0 in Q2 2015.
• Historically, Non-Current Deffered Revenue has averaged $86833.1 across 3 years, with a median of $6455.0 in 2016.
• Across the five-year window, Non-Current Deffered Revenue jumped 466.94% in 2016 and slumped 99.14% in 2017, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $383036.0 in 2015, then tumbled by 98.75% to $4787.0 in 2016, then sank by 69.69% to $1451.0 in 2017.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1451.0 in Q2 2017, $3119.0 in Q1 2017, and $4787.0 in Q4 2016.